- Active, not recruiting
NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.
Updated: Sep 25, 2022
EMN - European Myeloma Network
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
This protocol is a single-arm, three-cohort, phase II multicenter study designed to assess the safety and the efficacy of three all-oral combinations: Velcade with continuous low-dose melphalan and prednisone (VMP) or with continuous low-dose cyclophosphamide and prednisone (VCP) or Velcade with low-dose prednisone could be effective and well tolerated (VP).
Sponsor
Collaborator
Fondazione EMN Italy Onlus
ClinicalTrials.gov Identifier: NCT01190787
Official Title: A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients
First Posted : August 30, 2010
Click here for details on ClinicalTrials.gov
Drug: velcade subcutaneous melphalan prednisone
Drug: velcade cyclophosphamide prednisone
Drug: velcade prednisone
Haematologica; 2020
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
Blood; 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
MYELOMA FRAILTY SCORE CALCULATOR
Locations
Italy